293 related articles for article (PubMed ID: 14500573)
1. Bone is a target for the antidiabetic compound rosiglitazone.
Rzonca SO; Suva LJ; Gaddy D; Montague DC; Lecka-Czernik B
Endocrinology; 2004 Jan; 145(1):401-6. PubMed ID: 14500573
[TBL] [Abstract][Full Text] [Related]
2. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
Lazarenko OP; Rzonca SO; Suva LJ; Lecka-Czernik B
Bone; 2006 Jan; 38(1):74-84. PubMed ID: 16137931
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
Ali AA; Weinstein RS; Stewart SA; Parfitt AM; Manolagas SC; Jilka RL
Endocrinology; 2005 Mar; 146(3):1226-35. PubMed ID: 15591153
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone decreases bone mass and bone marrow fat.
Harsløf T; Wamberg L; Møller L; Stødkilde-Jørgensen H; Ringgaard S; Pedersen SB; Langdahl BL
J Clin Endocrinol Metab; 2011 May; 96(5):1541-8. PubMed ID: 21367933
[TBL] [Abstract][Full Text] [Related]
5. Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I.
Ackert-Bicknell CL; Shockley KR; Horton LG; Lecka-Czernik B; Churchill GA; Rosen CJ
Endocrinology; 2009 Mar; 150(3):1330-40. PubMed ID: 18948404
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.
Sorocéanu MA; Miao D; Bai XY; Su H; Goltzman D; Karaplis AC
J Endocrinol; 2004 Oct; 183(1):203-16. PubMed ID: 15525588
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone.
Lazarenko OP; Rzonca SO; Hogue WR; Swain FL; Suva LJ; Lecka-Czernik B
Endocrinology; 2007 Jun; 148(6):2669-80. PubMed ID: 17332064
[TBL] [Abstract][Full Text] [Related]
8. Insulin sensitization by a novel partial peroxisome proliferator-activated receptor γ agonist with protein tyrosine phosphatase 1B inhibitory activity in experimental osteoporotic rats.
Kubo M; Fukui M; Ito Y; Kitao T; Shirahase H; Hinoi E; Yoneda Y
J Pharmacol Sci; 2014; 124(2):276-85. PubMed ID: 24553405
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
[TBL] [Abstract][Full Text] [Related]
10. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone).
Sottile V; Seuwen K; Kneissel M
Calcif Tissue Int; 2004 Oct; 75(4):329-37. PubMed ID: 15549648
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Prolyl Hydroxylase Domain Protein in the Rosiglitazone-Induced Suppression of Osteoblast Differentiation.
Kang JH; Kwak HJ; Choi HE; Kim J; Hong S; Kim OH; Oh BC; Cheon HG
PLoS One; 2015; 10(9):e0139093. PubMed ID: 26418009
[TBL] [Abstract][Full Text] [Related]
12. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.
Grey A; Bolland M; Gamble G; Wattie D; Horne A; Davidson J; Reid IR
J Clin Endocrinol Metab; 2007 Apr; 92(4):1305-10. PubMed ID: 17264176
[TBL] [Abstract][Full Text] [Related]
13. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.
Li YY; Wu HS; Tang L; Feng CR; Yu JH; Li Y; Yang YS; Yang B; He QJ
Pharmacol Res; 2007 Oct; 56(4):335-43. PubMed ID: 17889553
[TBL] [Abstract][Full Text] [Related]
14. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
Burris TP; Pelton PD; Zhou L; Osborne MC; Cryan E; Demarest KT
Mol Endocrinol; 1999 Mar; 13(3):410-7. PubMed ID: 10076998
[TBL] [Abstract][Full Text] [Related]
15. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation.
Lecka-Czernik B; Moerman EJ; Grant DF; Lehmann JM; Manolagas SC; Jilka RL
Endocrinology; 2002 Jun; 143(6):2376-84. PubMed ID: 12021203
[TBL] [Abstract][Full Text] [Related]
16. Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment.
Djazayeri K; Szilvássy Z; Peitl B; Németh J; Nagy L; Kiss A; Szabó B; Benko I
Eur J Pharmacol; 2005 Oct; 522(1-3):122-9. PubMed ID: 16213483
[TBL] [Abstract][Full Text] [Related]
17. The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice.
Wang C; Li H; Chen SG; He JW; Sheng CJ; Cheng XY; Qu S; Wang KS; Lu ML; Yu YC
J Bone Miner Metab; 2012 Nov; 30(6):630-7. PubMed ID: 22886403
[TBL] [Abstract][Full Text] [Related]
18. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo.
Lecka-Czernik B; Ackert-Bicknell C; Adamo ML; Marmolejos V; Churchill GA; Shockley KR; Reid IR; Grey A; Rosen CJ
Endocrinology; 2007 Feb; 148(2):903-11. PubMed ID: 17122083
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor beta2 inhibits adipocyte differentiation induced by skeletal unloading in rat bone marrow stroma.
Ahdjoudj S; Lasmoles F; Holy X; Zerath E; Marie PJ
J Bone Miner Res; 2002 Apr; 17(4):668-77. PubMed ID: 11918224
[TBL] [Abstract][Full Text] [Related]
20. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
Kim HJ; Jung TW; Kang ES; Kim DJ; Ahn CW; Lee KW; Lee HC; Cha BS
Metabolism; 2007 May; 56(5):676-85. PubMed ID: 17445544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
